DWK Life Sciences acquires Müller + Müller-Joh.

The world’s lead­ing man­u­fac­tur­er of lab­o­ra­to­ry glass and life sci­ence pack­ag­ing mate­ri­als, DWK Life Sci­ences, announces the sign­ing of a defin­i­tive pur­chase agree­ment of Müller + Müller at August 21^st, 2020. Müller + Müller is one of the lead­ing Ger­man man­u­fac­tur­ers of pri­ma­ry pack­ag­ing mate­ri­als made of tubu­lar glass for the phar­ma­ceu­ti­cal indus­try. The com­pa­ny will become part of the DWK Life Sci­ences group upon clos­ing, which is expect­ed for Sep­tem­ber. Müller + Müller will con­tin­ue to serve its cus­tomers under the same name and will con­tin­ue to be man­aged by CEO Flo­ri­an Müller-Stauch. Dr. Huber­tus Müller-Stauch (own­er of the com­pa­ny Müller + Müller) will join the advi­so­ry board of DWK Life Sci­ences to sup­port the fur­ther expan­sion of the phar­ma pack­ag­ing division.

Müller + Müller is based in Holz­min­den in Low­er Sax­ony, Ger­many, and cur­rent­ly employs 135 staff. The fam­i­ly-run com­pa­ny is a key play­er in the man­u­fac­ture of vials and has a long his­to­ry of over 95 years. Thanks to its state-of-the-art tech­nol­o­gy and con­tin­u­ous process opti­mi­sa­tion, Müller + Müller meets the high­est qual­i­ty require­ments for phar­ma­ceu­ti­cal pack­ag­ing. Every year approx. 300 mil­lion glass type I vials are pro­duced at its Holz­min­den site in accor­dance with GMP guide­lines. Type I borosil­i­cate glass is an excel­lent mate­r­i­al for stor­ing vac­cines as the glass is vir­tu­al­ly inert. This means that the con­tain­er glass does not react with its con­tents and thus rep­re­sents the stan­dard in vac­cine packaging.

“Acquir­ing the fam­i­ly busi­ness Müller + Müller is a sig­nif­i­cant strate­gic step for us in expand­ing our activ­i­ties in the mar­ket for phar­ma­ceu­ti­cals pack­ag­ing,” explains CEO of DWK Life Sci­ences, Armin Reiche. “We are not just invest­ing in an impor­tant growth mar­ket here, but also in a com­pa­ny that boasts first class pro­duc­tion tech­nol­o­gy and high­ly reli­able products.”

“Dri­ven by the high demand of the vac­cine indus­try for vials, expan­sion of our pro­duc­tion capac­i­ties is the next log­i­cal step,” says Flo­ri­an Müller-Stauch, CEO of Müller + Müller. “We are delight­ed to have found a strong and reli­able part­ner in DWK who will allow us to fur­ther devel­op our business.”

DWK Life Sci­ences is a port­fo­lio com­pa­ny of One Equi­ty Part­ners, a mid­dle mar­ket pri­vate equi­ty firm that builds mar­ket-lead­ing com­pa­nies by iden­ti­fy­ing and exe­cut­ing trans­for­ma­tive busi­ness com­bi­na­tions and part­ner­ing with man­age­ment teams to pro­vide oper­a­tional sup­port to accel­er­ate growth.